IL296835A - Process for preparing parp inhibitor, crystalline forms, and uses thereof - Google Patents
Process for preparing parp inhibitor, crystalline forms, and uses thereofInfo
- Publication number
- IL296835A IL296835A IL296835A IL29683522A IL296835A IL 296835 A IL296835 A IL 296835A IL 296835 A IL296835 A IL 296835A IL 29683522 A IL29683522 A IL 29683522A IL 296835 A IL296835 A IL 296835A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- crystalline form
- hydrate
- sesqui
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015088003 | 2015-08-25 | ||
| PCT/CN2016/096200 WO2017032289A1 (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296835A true IL296835A (en) | 2022-11-01 |
Family
ID=58099633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296835A IL296835A (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| IL257442A IL257442B2 (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257442A IL257442B2 (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms and their uses |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10457680B2 (enExample) |
| EP (1) | EP3341375B1 (enExample) |
| JP (1) | JP6940039B2 (enExample) |
| KR (1) | KR20180041748A (enExample) |
| CN (2) | CN112521390A (enExample) |
| AU (1) | AU2016312011B2 (enExample) |
| BR (1) | BR112018003634B1 (enExample) |
| CA (1) | CA2994895A1 (enExample) |
| EA (1) | EA037366B1 (enExample) |
| IL (2) | IL296835A (enExample) |
| MX (1) | MX385450B (enExample) |
| NZ (1) | NZ739876A (enExample) |
| TW (1) | TWI736550B (enExample) |
| WO (1) | WO2017032289A1 (enExample) |
| ZA (1) | ZA201800765B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ624063A (en) | 2011-12-31 | 2016-09-30 | Beigene Ltd | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| WO2017032289A1 (en) | 2015-08-25 | 2017-03-02 | Beigene, Ltd. | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| CN110087730B (zh) * | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| TW201840564A (zh) | 2017-02-28 | 2018-11-16 | 英屬開曼群島商百濟神州有限公司 | 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途 |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| US12121518B2 (en) | 2017-03-09 | 2024-10-22 | The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College | PARP-1 and methods of use thereof |
| US20200155567A1 (en) * | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
| TWI826446B (zh) | 2018-05-18 | 2023-12-21 | 瑞士商諾華公司 | Tlr7/tlr8抑制劑之晶型 |
| EP3801550A4 (en) * | 2018-06-01 | 2022-02-16 | BeiGene, Ltd. | MAINTENANCE THERAPY OF A PARP INHIBITOR IN THE TREATMENT OF GASTRIC CANCER |
| USD926356S1 (en) * | 2019-03-14 | 2021-07-27 | Tuanfang Liu | Battery for electronic cigarette |
| CN113004279B (zh) * | 2019-05-10 | 2023-01-06 | 百济神州(苏州)生物科技有限公司 | 一种控制含parp抑制剂倍半水合物产物的含水量的方法 |
| CN111171002B (zh) * | 2019-05-16 | 2021-04-06 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的制备方法 |
| CN111171001B (zh) * | 2019-05-16 | 2022-04-29 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的结晶方法 |
| CN112007011B (zh) * | 2019-05-31 | 2024-07-23 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂微丸胶囊及其制备工艺 |
| MX2021014339A (es) | 2019-05-31 | 2022-01-06 | Beigene Ltd | Preparacion de granulo inhibidor de parp y proceso de preparacion del mismo. |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05006B1 (et) | 1999-01-11 | 2008-04-15 | Agouron Pharmaceuticals, Inc. | Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid |
| US6887996B2 (en) * | 2000-12-01 | 2005-05-03 | Guilford Pharmaceuticals Inc. | Compounds and their use |
| SI1585749T1 (sl) * | 2003-01-09 | 2008-10-31 | Pfizer | Derivati diazepinoindola kot inhibitorji kinaze |
| ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| NZ624063A (en) * | 2011-12-31 | 2016-09-30 | Beigene Ltd | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| WO2017032289A1 (en) | 2015-08-25 | 2017-03-02 | Beigene, Ltd. | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| CN110087730B (zh) * | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| TW201840564A (zh) * | 2017-02-28 | 2018-11-16 | 英屬開曼群島商百濟神州有限公司 | 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途 |
| US20200155567A1 (en) * | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
| CN113004279B (zh) * | 2019-05-10 | 2023-01-06 | 百济神州(苏州)生物科技有限公司 | 一种控制含parp抑制剂倍半水合物产物的含水量的方法 |
-
2016
- 2016-08-22 WO PCT/CN2016/096200 patent/WO2017032289A1/en not_active Ceased
- 2016-08-22 CN CN202011223061.6A patent/CN112521390A/zh active Pending
- 2016-08-22 NZ NZ739876A patent/NZ739876A/en not_active IP Right Cessation
- 2016-08-22 KR KR1020187008548A patent/KR20180041748A/ko not_active Ceased
- 2016-08-22 EP EP16838548.2A patent/EP3341375B1/en not_active Not-in-force
- 2016-08-22 BR BR112018003634-0A patent/BR112018003634B1/pt not_active IP Right Cessation
- 2016-08-22 CA CA2994895A patent/CA2994895A1/en active Pending
- 2016-08-22 IL IL296835A patent/IL296835A/en unknown
- 2016-08-22 US US15/753,993 patent/US10457680B2/en active Active
- 2016-08-22 EA EA201890547A patent/EA037366B1/ru not_active IP Right Cessation
- 2016-08-22 IL IL257442A patent/IL257442B2/en unknown
- 2016-08-22 JP JP2018510352A patent/JP6940039B2/ja not_active Expired - Fee Related
- 2016-08-22 AU AU2016312011A patent/AU2016312011B2/en not_active Ceased
- 2016-08-22 CN CN201680048637.5A patent/CN107922425B/zh active Active
- 2016-08-22 MX MX2018002322A patent/MX385450B/es unknown
- 2016-08-24 TW TW105127160A patent/TWI736550B/zh not_active IP Right Cessation
-
2018
- 2018-02-06 ZA ZA201800765A patent/ZA201800765B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201800765B (en) | 2019-10-30 |
| IL257442B2 (en) | 2023-03-01 |
| NZ739876A (en) | 2022-09-30 |
| EP3341375A1 (en) | 2018-07-04 |
| US10457680B2 (en) | 2019-10-29 |
| EP3341375A4 (en) | 2019-01-16 |
| JP6940039B2 (ja) | 2021-09-22 |
| BR112018003634A8 (pt) | 2023-01-17 |
| AU2016312011A1 (en) | 2018-03-08 |
| CA2994895A1 (en) | 2017-03-02 |
| KR20180041748A (ko) | 2018-04-24 |
| BR112018003634A2 (en) | 2018-11-21 |
| AU2016312011B2 (en) | 2021-02-04 |
| EA037366B1 (ru) | 2021-03-18 |
| TWI736550B (zh) | 2021-08-21 |
| US20190177325A1 (en) | 2019-06-13 |
| IL257442B (en) | 2022-11-01 |
| WO2017032289A1 (en) | 2017-03-02 |
| CN112521390A (zh) | 2021-03-19 |
| MX2018002322A (es) | 2018-04-11 |
| TW201718586A (zh) | 2017-06-01 |
| JP2018528199A (ja) | 2018-09-27 |
| MX385450B (es) | 2025-03-18 |
| BR112018003634B1 (pt) | 2023-11-21 |
| CN107922425B (zh) | 2021-06-01 |
| CN107922425A (zh) | 2018-04-17 |
| IL257442A (en) | 2018-04-30 |
| EP3341375B1 (en) | 2022-04-13 |
| EA201890547A1 (ru) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296835A (en) | Process for preparing parp inhibitor, crystalline forms, and uses thereof | |
| US20230049952A1 (en) | Methods and compounds for restoring mutant p53 function | |
| CN113874019A (zh) | 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合 | |
| IL282988B1 (en) | Methods of treating cystic fibrosis | |
| NZ735715A (en) | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | |
| IL290338B1 (en) | Solid dispersions containing sgc activator | |
| JP2018500377A (ja) | 癌の治療を目的とする、ユビキチン特異的プロテアーゼ７（ｕｓｐ７）阻害剤としてのピロロトリアジノン誘導体及びイミダゾトリアジノン誘導体 | |
| JP7636646B2 (ja) | Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応 | |
| EP3612527B1 (en) | Heterocyclic compounds useful as modulators of acetylcholine receptors | |
| IL269347B (en) | Ip6k inhibitors | |
| IL271910B2 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives inhibit ask1 | |
| IL303962A (en) | The tricyclic compound | |
| IL265523A (en) | A method of treating cancer through a combination of harmful substances and pk-DNA inhibitors | |
| TW201643143A (zh) | 抑制氧化壓迫引發的神經細胞死亡之化合物 | |
| CN115433187A (zh) | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 | |
| WO2021143922A1 (zh) | 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法 | |
| JPWO2016171142A1 (ja) | 複素環化合物 | |
| IL322451A (en) | Substituted tricyclic compounds | |
| CN119173510A (zh) | 一种羟基酰胺类衍生物及其应用 | |
| HK40040143A (en) | Process for preparing parp inhibitor, crystalline forms, and uses thereof | |
| TW202519531A (zh) | 含丙烯酮類生物抑制劑的晶型及其製備方法和應用 | |
| HK40063773A (en) | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases | |
| WO2021092892A1 (zh) | 喹啉或喹唑啉类化合物在制备抗肿瘤药物中的应用 |